HIV Breakthrough for Nigeria: New Prevention Drug Arrives in March

The National Agency for the Control of AIDS (NACA) has officially announced that Nigeria is set to receive its inaugural shipment of Lenacapavir (LEN), an innovative twice-yearly injectable drug designed for HIV prevention, by March 2026. This significant development underscores the federal government's unwavering commitment to enhancing HIV prevention strategies and accelerating progress towards achieving epidemic control across the nation.

Lenacapavir represents a major advancement in Pre-Exposure Prophylaxis (PrEP) options. Unlike daily oral PrEP regimens, LEN requires administration only twice a year, offering a substantially more convenient and potentially more effective alternative for individuals at a high risk of contracting HIV. This ease of use is anticipated to improve adherence rates and broaden the reach of HIV prevention efforts.

NACA further confirmed that Nigeria is meticulously preparing for a phased introduction and comprehensive rollout of the injectable LEN PrEP. This strategic implementation will target priority states, following a rigorous process that includes obtaining full regulatory approval, ensuring robust system readiness within the healthcare infrastructure, training essential personnel, and implementing extensive community engagement strategies to foster acceptance and understanding.

The federal government has already completed several critical rollout requirements. Notably, landscape and readiness assessments have been successfully conducted across ten key states: Akwa Ibom, Anambra, Benue, Cross River, Ebonyi, the Federal Capital Territory (FCT), Gombe, Kano, Kwara, and Lagos. These assessments are vital for identifying specific needs and tailoring the rollout approach to each region.

To support public awareness and facilitate smooth implementation, NACA has also proactively developed comprehensive Information, Education, and Communication (IEC) materials. These materials are designed to inform the public about the benefits of Lenacapavir, how it works, and its role in Nigeria's broader HIV prevention agenda, ensuring that communities are well-prepared and engaged in this crucial public health initiative.